Relugolix API
Lewens Labs develops and manufactures Relugolix API — oral GnRH receptor antagonist, an oral, once-daily GnRH receptor antagonist — used in advanced prostate cancer and women's health conditions, at its GMP facility in Gujarat, India.
Note for Lewens: populate CAS, formula, grade, DMF/CEP & registrations for Relugolix from the Regulatory master list.
Why Relugolix rewards process depth.
Relugolix involves a convergent route through several nitrogen heterocycles.
Lewens' integrated platform — process R&D, analytical development and manufacturing under one team — is built for exactly this kind of technically demanding molecule. We can support Relugolix as commercial supply, as a second source, or as a development and custom-synthesis programme through our CDMO platform.
Three ways to source Relugolix.
Ongoing supply
Reliable, on-specification commercial quantities of Relugolix API for your registered product.
Alternate supplier
De-risk your supply chain for Relugolix with a dependable additional or backup source.
Custom & CDMO
Process development, improvement or exclusive arrangements for Relugolix under NDA.
More in Oncology.
Relugolix API — FAQs.
Does Lewens manufacture Relugolix API?
Can Lewens supply Relugolix as a second source?
What is Relugolix used for?
Need Relugolix API?
Request specifications, samples or DMF/CEP documentation — or discuss a second-source or custom-synthesis programme.